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Abstract
The obligate intracellular bacterium Chlamydia exists as two distinct forms. Elementary bodies (EBs) are infectious and extra-
cellular, whereas reticulate bodies (RBs) replicate within a specialized intracellular compartment termed an ‘inclusion’.
Alternative persistent intra-cellular forms can be induced in culture by diverse stimuli such as IFNc or adenosine/EHNA. They
do not grow or divide but revive upon withdrawal of the stimulus and are implicated in several widespread human diseases
through ill-defined in vivo mechanisms. b-lactam antibiotics have also been claimed to induce persistence in vitro. The
present report shows that upon penicillin G (pG) treatment, inclusions grow as fast as those in infected control cells. After
removal of pG, Chlamydia do not revert to RBs. These effects are independent of host cell type, serovar, biovar and species
of Chlamydia. Time-course experiments demonstrated that only RBs were susceptible to pG. pG-treated bacteria lost their
control over host cell apoptotic pathways and no longer expressed pre-16S rRNA, in contrast to persistent bacteria induced
with adenosine/EHNA. Confocal and live-video microscopy showed that bacteria within the inclusion fused with lysosomal
compartments in pG-treated cells. That leads to recruitment of cathepsin D as early as 3 h post pG treatment, an event
preceding bacterial death by several hours. These data demonstrate that pG treatment of cultured cells infected with
Chlamydia results in the degradation of the bacteria. In addition we show that pG is significantly more efficient than
doxycycline at preventing genital inflammatory lesions in C. muridarum-C57Bl/6 infected mice. These in vivo results support
the physiological relevance of our findings and their potential therapeutic applications.
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Introduction
Obligate intracellular bacteria of the genus Chlamydiaceae are the
causal agents of a spectrum of human diseases of public health
importance. Chlamydia trachomatis (C.t) infections remain the most
frequent sexually transmitted bacterial disease, and the leading
cause of infectious blindness (trachoma) worldwide [1,2].
Infection by Chlamydiaceae follows a unique developmental cycle,
lasting 30–100 hours, depending on the strain and species. Host
cell infection is caused by a small, infectious yet metabolically inert
form, the elementary body (EB, 0.3 mm diameter). Upon
internalization, EBs differentiate into a larger, metabolically active
form, the ‘reticulate body’ (RB, 1 mm). RBs forge a replicative
niche within a membrane-bound compartment, termed an
‘inclusion’, by hijacking key eukaryotic processes. This includes
blocking cellular apoptosis and the fusion of lysosomes with the
inclusion [3–7]. RBs subsequently replicate by binary fission, prior
to re-differentiating into EBs, which are released to re-infect
neighboring cells [8].
Primary chlamydial infections are generally cleared by the host
innate and adaptive immune responses. However, when chronic
infection persists, local inflammatory responses can cause fibrosis
and mucosal scarring and lead to severe sequelae in ocular tissue
including blindness, and in the genital tract, including infertility,
ectopic pregnancy and various gestation pathologies. Recent
studies (reviewed in [2,9]) argue that chronic infections are caused
by an atypical intracellular form of the bacteria termed a
‘persistent’ form (PF). PFs have a low metabolic activity and are
suspected to reside in tissues for years. They are non-infectious and
hence cannot grow ex vivo. Several different host cell culture
models have been developed to study PFs, after in vitro induction of
persistence [9,10]. Physiologically, persistence may be induced by
locally high levels of IFNc produced in response to infection, or by
adenosine, released after lysis of infected neighboring cells.
Consistent with this, the chlamydial developmental cycle can
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indeed be manipulated by adenosine in cell culture [11]. It is
generally agreed that a persistent state is characterized by
inclusion growth arrest and development from RBs of few non-
dividing, non-infectious and slightly enlarged (, 2 mm in
diameter) PFs. PFs can be reactivated and become infectious
when the persistence inducer is removed, a common feature in all
classical persistence models [2,9,10].
b-lactam antibiotics have also been claimed to induce
chlamydial persistence in cultured cells [2,9,10]. Strikingly, while
Chlamydiaceae are susceptible to this class of antibiotic, the
recognized target, peptidoglycan, is absent: this feature is known
as the ‘‘Chlamydia paradox’’ [12]. In the 1970s, penicillin G (pG)
treatment of Chlamydia-infected cells was shown to affect RB
division and induce apparent PFs [13–20]. Although current
literature favors the hypothesis that b-lactam antibiotics induce
Chlamydiaceae to persist in vitro and in vivo, older observations
suggested that inclusion and bacterial morphologies following pG
treatment differed from archetypal PFs, and that pG-treated
Chlamydiaceae could not become infectious again after the
withdrawal of pG [15,21,22].
Our work shows that pG treatment does not affect the growth
kinetics of the inclusion, a hallmark of classical persistence
inducers, but triggers the formation of much larger (5–10 mm)
abnormal bacterial forms. Moreover, we demonstrate that pG
withdrawal from Chlamydia-infected cultures does not restore
infectivity. We show that pG treatment causes chlamydial death
in multiple host cell types by inducing the entry of host lysosomes
into the bacterial inclusion. Finally, our in vivo experiments show
that mice vaginally-infected with C. muridarum, and treated per os
by pG or doxycycline, an antibiotic of the Tetracycline family,
eliminate the bacterial load in the lower genital tract much faster
than untreated infected mice. However, only pG-treated mice are
significantly protected from severe genital inflammatory lesions of
the genital tract, when compared to untreated infected mice or
infected mice treated with doxycycline. These data support the
physiological relevance of our in vitro observations. They also
suggest that pG-treatment of human Chlamydia genital infections
could help reduce inflammatory lesions in the upper genital tract.
Materials and Methods
Ethics Statement
Six week-old C57Bl/6 female mice were housed in specific
pathogen-free conditions and used according to European and
NIH institutional guidelines. The use of mice in the manuscript
was approved by the local Institutional Animal Care and Use
(IACUC) and ethics Committee, officially referred to as "Animal
Experimentation Ethical Committee, Buffon" (CEEA-40). The
approved protocol number is CEB-05-2012. The current version
of this protocol is valid until March 29 2015. Vaginal infection was
performed under pentobarbital anesthesia, and all efforts were
made to minimize suffering or discomfort.
Bacterial strains, Cultures and reagents
All cell types (HeLa, RL-95-2, THP-1) were obtained from and
cultured as recommended by ATCC (Manassas, VA), in 75 cm2
tissue culture flasks for maintenance and in 12- or 24-well plates
containing coverslips, or in Lab-Tek chamber slides, when
appropriate. THP-1 cells were differentiated into macrophages
using PMA overnight at 0.25 mM in culture medium. C. trachomatis
serovar L2 was from ATCC, C. trachomatis serovar D was kindly
provided by Dr. De Barbeyrac (University of Bordeaux II,
Bordeaux, France) and C. muridarum was a gift from Dr. Roger
Rank (University of Arkansas, Little Rock, Arkansas, United
States). Bacteria were routinely propagated in HeLa cells as
previously described and stored at –80uC in sucrose-phosphate-
glutamic acid (SPG) buffer (10 mM sodium phosphate [8 mM
Na2HPO4–2 mM NaH2PO4], 220 mM sucrose, 0.50 mM
Lglutamic acid) for later use [23]. The number of bacterial
inclusion forming units (IFU) was determined using a previously
described method [24]. Culture media (DMEM, HAMF F12,
RPMI-1640), fetal calf serum and gentamycin were purchased
from Invitrogen (Carlsbad, CA, USA). Cycloheximide (CHX),
staurosporine (STS), adenosine (Ad), erythro-9-(2-Hydroxy-3-
nonyl)adenine (EHNA), penicillin G (pG) and doxycycline (Dox)
were from Sigma-Aldrich (St Louis, MO, USA). Lysotracker,
Hoescht and pepstatin-FL-BODIPY were from Invitrogen (Carls-
bad, CA, USA). Anti-Chlamydia genus-FITC antibody was from
Argene (Argen Biosoft 12-114, Varhilles, France), anti-cathepsin D
from Santa Cruz (Santa Cruz Biotechnology, CA, USA) and
secondary antibody from Beckman Coulter (Fullerton, CA, USA).
Chlamydial infection of cultured cells and treatment with
pG
To examine the effects of pG on chlamydial infection, cells were
cultured up to 70% confluence in culture medium containing no
antibiotic and no CHX (infection medium) and were infected
either with C. trachomatis or C. muridarum at an inclusion forming
unit (IFU) of 1. Infections were performed at 37uC for 90 min,
then cells were washed to eliminate dead bacteria. At different
times post infection (hpi), culture medium was replaced by
infection medium or medium containing different concentrations
of pG (.01 to 100 IU/mL). At different times after infection and
pG treatment, cultures were either fixed in 4% neutral-buffered
paraformaldehyde for 30 min to be processed for microscopy, or
harvested for infectivity measurements of the progeny (titration
assay) as previously described [23].
Induction of chlamydial persistence with adenosine/
EHNA treatment
Persistence of the L2 strain of C.trachomatis was induced as
previously described [11] with minor modifications. Briefly, HeLa
cells were infected with C. trachomatis serovar L2 at an IFU of 0.5. At
1 hpi, Ad (400 mM) was added to the culture medium and replaced
every hour from 1 to 8 hpi. Then, medium containing both Ad
(400 mM) and EHNA (25 mM) was added to prevent adenosine
degradation. This medium was replaced at 24 hpi and every 8 h
thereafter to maintain the persistent phenotype.
Reversion assay
HeLa monolayers grown on coverslips were infected with C.
trachomatis serovar L2 and treated with either different concentra-
tions of pG or with Ad/EHNA as described. At 24 hpi or 32 hpi,
the culture was extensively washed and medium was replaced by
infection medium (reversion step). At 75 hpi, the cell layer and
culture medium were collected and a titration assay performed as
previously described [23]. To examine whether inhibition of host
cell protein synthesis could allow the recovery of infectivity of the
progeny from pG-treated cells, HeLa cells were treated with CHX
at 1 mg/mL 4 h prior to infection. From 3 hpi to 24 hpi, pG
(100 IU/mL) was added to the culture medium containing CHX
or not. At 24 hpi, pG was removed, and culture was continued up
to 100 hpi in the presence or absence of CHX, before titration
assays were performed.
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Preparation of RNA and analysis of gene expression
105 HeLa cells were seeded prior to infection and incubation
with either pG or Ad/EHNA. At 75 hpi, total RNA was isolated
using an RNeasy Mini Plus Kit (Qiagen, Hilden, Germany).
DNase I treatment was performed (1 h at 37uC). RNA was
reverse-transcribed using random hexamer primers and an affinity
Script MT reverse transcriptase (Agilent, Santa Clara, CA),
according to the manufacturer’s instructions. Control PCR
reactions were performed using isolated RNA to verify the
absence of genomic DNA contamination. PCR was processed
using Taq Polymerase (Invitrogen, Carlsbad, CA, USA) and
primers designed for bacterial pre-16S rRNA (Fw: gCCAgTA-
TAgATgCTTgTgAggA Rv: CTgCAgCCTCCgTAgAgTCTggg-
CAgTgTC) and eukaryotic GAPDH rRNA (Fw: gAgTCAACg-
gATTTggTCgT Rv: TTgATTTTggAgggATCTCg) [25]. Semi-
quantification of the resulting PCR products was achieved by
agarose gel electrophoresis and UV detection.
Sensitivity to apoptosis
HeLa cells were infected with C. trachomatis serovar L2 and
treated with pG at either 2 hpi or 29 hpi. Cells were incubated
with 1 mM of STS at 31 hpi, fixed at 40 hpi and stained with
Hoechst and a FITC-conjugated anti-Chlamydia antibody. More
than 10 microscopy fields were scored for each condition in
triplicate. Under these conditions, STS treatment induces
apoptosis in 90–100% of uninfected cells. Percentages of infected
cells containing apoptotic nuclei were calculated.
Confocal microscopy
Cells were cultured on coverslips and infected with Chlamydia.
When appropriate, cell layers were treated with pG at 3 hpi. Cells
were fixed at 24 hpi, permeabilized and incubated (2 h, RT) with
an anti-cathepsin D antibody diluted in PBS containing 1% (w/v)
BSA. After extensive washing, cells were stained for 1h at RT with
a Texas red-conjugated goat anti-rabbit IgG secondary antibody,
with a FITC-conjugated anti-Chlamydia antibody and then
counterstained for 5 min with Hoechst. Isotype controls were
used in all experiments. Coverslips were mounted and observed
using a confocal microscope (Leica, TCS Sp5 AOBS tandem,
Leica, Mannheim, Germany) equipped with two diode lasers (1
and 25 nW) emitting at 405 nm and 561 nm, respectively, and an
argon laser (100 nW) emitting at 488 nm. Emission signals were
recorded at 411–481 nm for Hoechst, 493–555 nm for FITC and
591–703 nm for Texas Red. Each experiment was performed,
acquired and analysed similarly, and repeated at least three times.
Labeling of cultured cells with lysotracker-red
Cells cultured on glass-bottomed Lab,Tek chamber slides
(Thermo Fisher Scientific, Roskilde, DK) were infected and
treated with pG at 3 hpi. At 22 hpi, cell layers were incubated with
10 mM of lysotracker-red diluted in DMEM (30 min, 37uC).
Medium was replaced by infection medium and slides were placed
in an environmental chamber at 37uC with 5% CO2 and observed
in time lapse videomicroscopy using a Leica confocal microscope
equipped with a tandem resonant scanner. Excitation was
performed at 561 nm using a diode laser (1 nW) and emission
signal was collected between 565 and 641 nm. Images were
acquired every 2 min for up to 4 h.
Cathepsin D-active site staining
The active sites of cathepsin D have been stained using the
fluorescent Bodipy-pepstatin-FL probe (Invitrogen, Carlsbad, CA,
USA) [26]. Briefly, infected cells treated or not with pG were fixed
at 32 hpi, permeabilized and washed with sodium acetate buffer
(pH 4.5). Coverslips were incubated for 1 h at RT with 5 mM of
Bodipy-pepstatin FL diluted in sodium acetate buffer. After
extensive washes in Tween-acetate buffer, coverslips were
mounted and observed by fluorescence microscopy.
Mouse genital tract infection and antibiotic treatments
Six week-old C57Bl/6 female mice were purchased from
Charles River Laboratories (France). Animals were randomly
divided into 4 groups: non-infected (n= 10), infected non-treated
(n= 35), infected + Dox (n= 29), infected + pG (n= 36). Four days
prior to infection, animals received 2.5 mg of progesterone
subcutaneously (Depo-Provera, Pfizer, France) to synchronize
their estrus cycle. Mice to be infected were anesthetized by intra-
peritoneal injection of 24 mg of pentobarbitone per kg of body
weight and were inoculated intra-vaginally with 36106 IFUs of
live C. muridarum organisms in 20 ml of SPG buffer. Non-infected
animals received the same volume of SPG. From 10 up to 30 days
after infection, 2 groups of mice received either Dox or pG, daily
at 10 mg/ml in drinking water supplemented with 7.5% sucrose.
Control infected non-treated mice were given drinking water
supplemented with 7.5% sucrose only. The amount of circulating
antibiotic was determined for each group by measuring the daily
volume drunk by mice (daily weighing of the bottles) and using the
factors of intestinal absorption and excretion for each molecule.
Depending on the experiment, we calculated that mice treated
with Dox received from 6.55 to 11.42 mmol/animal/day and mice
treated with pG received from 3.65 to 8.72 mmol/animal/day.
Monitoring vaginal Chlamydia live infection
For the three groups of infected animals (infected non-treated
(n= 5), infected + Dox (n = 5), infected + pG (n= 6)), the vaginal
bacterial load was monitored by collecting vaginal swabs every 2
or 3 days after intra-vaginal bacterial infection, until 32 days post-
infection. Chlamydia organisms were recovered from swabs and
triplicates of serially diluted samples were used to infect HeLa cells
grown on 96 well plates. After 24 h in the presence of CHX (1 mg/
mL), cells were fixed using PFA 4% and stained using May-
Gru¨nwald Giemsa dyes. At least four random fields were counted
per well. Wells showing cytotoxicity were excluded. The total
number of IFU per swab was calculated based on the percentage
of infected cells, the total number of cells grown in each well, the
number of fields counted per coverslip, the average of triplicates,
the volume and the dilution factors of the recovered samples.
Average and standard deviation of total number of IFU/swab was
calculated for each group and each time point and converted into
log10.
Scoring of Uterine lesions
Mice from each group were sacrificed 90 days after infection
and the genital tract was isolated for pathology examination. Both
incidence and severity of fluid-filled cysts along the uterine horns
were recorded for each mouse and compared between different
groups. The severity of those cysts was scored based on their size.
Absence of lesion was scored as 0; cysts visible only with binocular
amplification were scored as 1; cysts smaller than 3 mm were
scored as 2; cysts larger than 3 mm were scored as 3.
Histopathology
Immediately after the evaluation of macroscopic uterine lesions,
the uterine horns were fixed in 4% buffered paraformaldehyde,
and embedded in paraffin. Transversal 5-mm sections were
performed in the middle part of the horns, stained with
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Hematoxylin and Eosin, and observed at a 40 X magnification.
Changes in morphology of the uterine horns and the presence of
inflammatory cell infiltrates were monitored.
Statistical analysis
Data are presented as the mean 6 standard deviation of ‘‘n’’
experiments, and p values were calculated using a two-tailed two-
sample equal variance Student’s t test. For qualitative data
analyses, the non-parametric Mann-Whitney test was used.
Statistically significant differences are noted as follows: (*
p,0.05), (** p,0.01), (*** p,0.001).
Results
pG induces abnormal bacterial forms in Chlamydia-
infected cells
Treatment of infected cell cultures with pG, or adenosine
associated with EHNA, has been reported to induce chlamydial
persistence [1,2,11]. In the literature, persistence is defined by
inclusion stasis, and reversion, i.e. the recovery of infectious activity
following the removal of the persistence inducer.
To investigate the effects of pG further, we initially compared
inclusion morphology during pG treatment to IFNc or iron
deprivation, the last two being assumed to be physiological
inducers of persistence in vivo. However, neither IFNc nor iron
deprivation induced persistence in 100% of infected cells,
hampering subsequent transcriptomic or biochemical analyses of
persistent cells. Thus, we opted for the comparison of pG with
adenosine (Ad)/EHNA treatment, which induced persistence in
nearly all infected cells. The size of persistent bacterial inclusions
remained constant for as long as one week (Figure 1A, after a 4
day treatment with Ad/EHNA). Within these inclusions, the
average diameter of bacterial PFs was 2–3 mm. Both the static
inclusions and the modest size of the PFs induced by Ad/EHNA
treatment are characteristic of classical chlamydial persistence in
vitro. In contrast to the bacterial inclusions produced in this
persistence model (Ad/EHNA), inclusions produced in infected
cells treated by pG are growing at the same rate as the inclusions
developing in untreated cells, both lysing at 100 hpi. The diameter
of abnormal bacteria (5–10 mm) induced by pG treatment was
much larger than typical PFs. Both the inclusion growth and the
size of bacterial forms following pG treatment strongly suggest that
Chlamydia fail to enter a persistent state. We verified that the
development of growing inclusions containing unusually large
bacterial forms was independent of the host cell type or the
serovar, biovar or species of Chlamydia (Figure S1A). Consequently,
we conclude that unlike Ad/EHNA, pG treatment leads to the
formation of very enlarged bacterial bodies, which we call ‘‘pG-
forms’’, contained within a growing inclusion, a phenotype
inconsistent with classical persistence.
Another hallmark of classical persistence is the resumption of
inclusion growth and the reemergence of infectious progeny
following the withdrawal of the persistence inducer. Thus, the
infectious capacity of bacteria after pG or Ad/EHNA removal was
assessed (Figure 1B). A 75 hpi, we observed a significant bacterial
growth (x250) when Ad/EHNA was withdrawn at 32 hpi. The
growth was non-significant when pG was removed at the same
time point (Figure 1B). To rule out any dose-dependent effect of
the antibiotic and the possibility that infectious bacteria can be
released from the host cells during pG-treatment, we performed
two different experiments (Figure S1B and Figure 1C).
Using serial dilutions of pG, we showed that no infectious
bacteria was observed in or out of the host cell at the dose of 1 IU/
mL of pG (Figure 1C). This is also confirmed when pG was
withdrawn at 48 hpi (Figure S1B). However, at concentrations
lower than 0.1 IU/mL pG was less effective, most probably
resulting from incomplete bactericidal efficiency and not from
reversion (Figure S1B). This lack of reversion in vitro has also been
observed for C. muridarum, down to 0.3 IU/mL (data not shown).
This demonstrates that a second feature of classical chlamydial
persistence, reversion upon removal of the persistence inducer, is
also not observed following pG treatment.
Since our results appeared at odds with part of the literature
claiming that pG induced persistence of Chlamydiaceae, we
compared our experiments to previously reported protocols. Most
of the groups that had reported reversion post pG-treatment had
performed pG-treatment of infected cells in the presence of
cycloheximide (CHX) to lower cell proliferation during infection.
We performed reversion experiments using pG in the presence or
absence of CHX. Surprisingly, these experiments showed that a
partial recovery of infectivity was detected after pG withdrawal
only in the presence of CHX, (Figure S1C). These conditions most
likely account for the data discrepancies and suggest that de novo
eukaryotic protein synthesis in the presence of pG prevents the
recovery of infectious bacterial progeny following pG withdrawal.
RBs are targeted by pG
Next, we determined the window of pG action during the C.
trachomatis cycle. When pG is added before 24 hpi and left in the
culture, infectious bacteria were never recovered at 75 hpi (Figure
2, white squares). When pG is added at 24 hpi or later, a fraction
of bacteria (increasing with hpi time) appear resistant to pG
treatment as infectious progeny are detectable.
When the presence of pG in the culture medium does not
exceed 12 hpi, the infectivity capacity of the progeny is not
affected (Figure 2, black diamonds). By contrast, increasing
efficacy against C.trachomatis is observed when the incubation with
pG exceed 12hpi (to become maximal at 24–32 hpi) before
removal. Altogether, these results indicate that chlamydial forms
present in infected cells up to 12 hpi, as well as newly divided
bacterial progeny present after 24 hpi, are not sensitive to pG.
This strongly suggests that pG acts on RBs during their
multiplication phase, whereas EBs appear insensitive to pG.
pG treatment kills Chlamydia
Given these effects, we measured the impact of pG treatment of
infected cells on the capacity of bacterial RBs to inhibit host cell
apoptosis and to transcribe a housekeeping precursor of 16S
rRNA, a classical key reporter of bacterial viability. When infected
cells were treated with STS at 21 hpi, only 11.569.8% became
apoptotic at 48 hpi while every uninfected control cell exhibited a
typical apoptotic nuclear staining (Figure 3A). Under identical
conditions, 70.4615.9% of pG treated-infected cells were
apoptotic. To evaluate the kinetics of this effect, infected cells
were treated with pG at 2 hpi or 29 hpi, and subsequently
incubated with STS at 31 hpi, and fixed 8h later. In both
conditions, we observed the same percentage of infected and
apoptotic cells (36.9615% and 38.4612.4%, respectively). These
results demonstrate that pG has a rapid effect on the bacteria,
since within a few hours, it causes an inhibition of the blocking of
cellular apoptotic pathways due to infection.
We tested the expression of pre-16S rRNA at 75 hpi, after
culture in different conditions: absence of drugs, presence of pG or
Ad/EHNA from 3 to 75 hpi, and following their removal at 32 hpi
in a reversion set up. During both treatments (Inf+pG and
Inf+Ad), transcription of pre-16S RNA was below the threshold of
detection (Figure 3B). However, upon withdrawal of these stimuli,
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only bacteria pretreated with Ad/EHNA resumed transcription of
pre-16S rRNA.
The absence of newly synthesized pre-16S rRNA upon the
removal of pG indicated that bacterial pG forms were no longer
transcriptionally active. We chose to monitor pre-16S rRNA as it
is critical for the bacterial survival and highly transcribed at a high
turn-over rate. Thus, its absence strongly suggests that pG-forms
are no longer viable.
Figure 1. Penicillin G (pG) treatment in vitro does not induce classical persistence of C. trachomatis. HeLa cells infected by C. trachomatis
serovar L2 were treated at 3 hpi with either pG (100 IU/mL) or Ad/EHNA, or left untreated. A- At different times after infection, cells were fixed and
stained using an anti-chlamydia antibody (green) and Hoechst (blue). Scale bar: 10 mm. B- pG or Ad/EHNA were removed at 32 hpi from culture
medium and culture was continued for 43 h. At 75 hpi, cells were processed for the titration of recovered infectious activity. C- HeLa cells infected by
C. trachomatis serovar L2 were treated at 3 hpi either with 1, 10 or 100 IU/mL pG or left untreated. In some samples (+), pG was removed at 24 hpi
from culture medium and culture was continued. At 48 hpi or 100 hpi, cell layers (left panel) and supernatants (right panel) were processed for the
titration of recovered infectious activity. All experiments have been repeated at least 3 times. * correspond to p, 0.05, ** correspond to p ,0.01,
*** correspond to p , 0.001. See also Figure S1
doi:10.1371/journal.pone.0083511.g001
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pG treatment induces the fusion of lysosomes with the
pG-forms of Chlamydia
As pG-treated Chlamydia appeared non-viable and non-infec-
tious, we examined how the bacteria were degraded, in particular
whether inclusions might be targeted by lysosomes in pG-treated
infected cells. Initially, acidic cellular compartments were tracked
using cathepsin D staining. Inclusions in untreated cells excluded
this marker while it accumulated in pG-forms (Figure 4A). This
cathepsin D accumulation was not restricted to a particular
bacterial strain or cell line, as equivalent results were obtained
when endometrial RL95-2 cells were infected with C.t serovar L2
or Hela cells with C.t serovar D (Figure S2). Furthermore, we
demonstrated that the recruited cathepsin D was enzymatically
active using a fluorescent active site-specific probe BODIPY-
pepstatin-FL (Figure 4B).
To monitor the process of cathepsin D recruitment and
activation, live labeling of lysosomes was performed using
lysotracker red. This probe revealed an extensive membrane
network, present only within the inclusion of pG-treated infected
cells (Figure 4C). Surprisingly, bright lysotracker puncta were
present within these inclusions (Figure 4C, inset), suggesting that
intact lysosomes entered the inclusions. We used confocal
videomicroscopy to study the dynamics of lysotracker-labelled
compartments in pG-treated infected cells. Compartments loaded
with lysotracker entered the inclusions and were recruited onto the
membrane of pG-forms (Figure 4D and movie S1). Our data show
that this unusual entry of lysotracker-positive compartments into
the bacterial inclusion leads to the accumulation of active
lysosomal protease cathepsin D within bacterial pG-forms. In
addition, we showed that this recruitment was observed after only
3 hours of incubation with pG (Figure 5A). This gradual
accumulation clearly preceded the decrease in pre-16S rRNA
transcription (Figure 5B), which strongly suggests that these events
are the cause of the bacterial death.
We sought to inhibit the fusion of lysosomes with the bacteria or
the activation of cathepsin D by incubating pG-treated infected
Figure 2. pG affects Chlamydia RB development. HeLa cells were infected by C. trachomatis serovar L2. Separate infected cultures were: A-
treated with pG (100 IU/mL) from indicated times post-infection up to 75 hpi, before the titration of recovered infectious activity.(white squares); or
B- treated with pG from 1 hpi until the indicated time. Cultures were continued after pG removal until 75 hpi, and then titrated for their recovered
infectious activity (black diamonds). The infectivity potential was expressed relatively to non-treated infected cells. The experiments have been
performed at least 3 times.
doi:10.1371/journal.pone.0083511.g002
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cells with NH4Cl or bafilomycin A1, prior and during infection
and pG treatment. Ammonium chloride has been shown to inhibit
the fusion of lysosomes with some cargo, while bafilomycin A1
specifically inhibits the H+-v-ATPase of the lysosome, regulating
the pH of this organelle. None of these treatments prevented the
accumulation of active cathepsin D in the pG-forms, nor avoided
the irreversible loss of infectivity observed in pG-treated infected
cells (data not shown). These results indicate that the fusion of
lysosomes with the bacteria in pG-treated infected cells occurs via
a pathway insensitive to NH4Cl. Moreover, the activation of
cathepsin D in pG forms is independent of the activation of a
lysosomal v-ATPAse.
pG oral treatment of mice vaginally-infected with C.
muridarum prevents the formation of uterine lesions
In order to assess the physiological relevance of our in vitro
observations, we decided to compare the effect of pG versus
Doxycycline (Dox) treatment (or no treatment as control) in
vaginally-infected mice. Four days after progesterone injection,
groups of mice were infected intra-vaginally with Chlamydia
muridarum (36106 IFUs). The infection was left to develop for 10
days before antibiotic treatments were given for 20 days (Figure
6A). Infected mice were treated with Dox or pG (10 mg/ml in
Figure 3. pG restores apoptotic pathways in the host cells and
inhibits RNA biosynthesis of Chlamydia. A- HeLa cells were
infected by C. trachomatis serovar L2 and treated with pG at 2 hpi or
left untreated. At 21 hpi, STS was added to the culture medium. Cells
were fixed at 48 hpi and stained as in Figure 1. Scale bar: 10 mm. Left
panel: data representation from the pictures after calculation of the
percentages of apoptotic infected cells. Right panel: Infected-HeLa cells
were treated with pG at either 2 hpi or 29 hpi or left untreated. Then,
STS was added at 31 hpi. Cells were fixed at 39 hpi and percentages of
apoptotic infected cells were determined and presented as in the left
panel. B- HeLa cells were infected by C. trachomatis serovar L2 and
treated at 1 hpi with either pG or Ad/EHNA, or left untreated. In some
experimental conditions (R), pG or Ad/EHNA were removed from
culture medium at 32 hpi and the culture was continued for 43 h. At 75
hpi, cells were processed to measure pre-16S and GAPDH RNA
expression. The experiments have been repeated 3 times. * correspond
to p, 0.05.
doi:10.1371/journal.pone.0083511.g003
Figure 4. pG induces lysosome entry into bacterial inclusions.
HeLa cells were infected by C. trachomatis serovar L2 and treated with
pG at 3 hpi or left untreated. At 24 hpi, cells were either fixed and
stained (A and B) or readily observed (C and D). Scale bar: 10 mm. The
experiments have been repeated at least 3 times. A- Staining of pG-
treated and untreated infected cells as in Figure 1, adding anti-
Cathepsin D labelling (red). B- Staining of pG-treated and untreated
infected cells using 5 mM BODIPY-pepstatin-FL (green) and Hoechst
(blue). C- Cells were incubated with lysotracker for 30 min at 37uC
before observation. Lysotracker localizes mainly in inclusions in pG-
treated infected cells. Details show strong bright spots in these
inclusions, suggesting a lysosome entry. Arrowhead: inclusion, arrow:
bright spot. DIC: differential interference contrast. D- Time lapse using a
confocal microscope with high resonance scanner. In grey, differential
interference contrast, in red, lysotracker. A lysosome (white arrow)
enters and stays inside an inclusion in pG-treated infected cells.
doi:10.1371/journal.pone.0083511.g004
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drinking water with sucrose, in both cases) or left untreated
(sucrose only in drinking water). The vaginal chlamydial shedding
was monitored on the indicated days for a period of 32 days
following bacterial challenge. As shown in Fig. 6B, untreated
infected mice resolved the vaginal infection around 32 days. Mice
infected and treated either by Dox or pG resolved the infection
significantly earlier than the control group, respectively by day 15
and day 18 post-infection, 5 and 8 days after the start of treatments
(no statistically significant difference between the two antibiotics).
These results suggest that both antibiotic treatments increased
early bacterial clearance following intravaginal C. muridarum
challenge.
Ninety days after infection, mice were sacrificed for macro-
scopic examination of their genital tract to detect possible
inflammatory lesions (fluid-filled cysts along uterine horns and
hydrosalpinges). Results are presented in Figures 6C-E. The
macroscopic examination of the uterine horns in the different
groups of mice gave unequivocal results. Fifty seven percent of
Figure 5. In the presence of pG, the recruitment of lysosomes precedes the death of Chlamydia trachomatis. HeLa cells were infected by
C. trachomatis serovar L2. At 15 hpi, cells were treated or not with pG for 3 h (18 hpi), 6 h (21 hpi), 15 h (30 hpi), or 24 h (39 hpi). A- Cells were either
fixed and stained as described in Figure 4 or B- processed to measure pre-16S and GAPDH RNA expression, as described in Figure 3. The experiments
have been repeated 3 times.
doi:10.1371/journal.pone.0083511.g005
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Figure 6. pG oral treatment prevents the development of uterine lesions in C57Bl/6 mice previously infected with C. muridarum. A-
Female mice were synchronized in their cycle by a Progesterone injection and four days later, were infected intravaginally with 36106 IFUs of C.
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non-treated infected mice presented deformations of the horns
with multiple fluid-filled cysts often associated with hydrosalpinges
(Figures 6C-E). These anomalies were as frequent and as severe in
Dox-treated animals than in infected non-treated mice (Figures 6D
and 6E). In contrast, 83% of mice from the pG-treated group had
no uterine lesions and 17% of the remaining mice developed less
severe lesions than untreated mice or even mice treated with Dox
(Figures 6D and 6E, statistically significant differences). We have
performed histopathology analyses on transversal sections of
paraffin-embedded uterine horns from mice in each group (Figure
S3). Hematoxylin/eosin staining of sections revealed important
anomalies in the non-treated infected group of mice compared to
the control non-infected tissues. The lumen was very enlarged and
distorted, the surrounding tissues were extended and all layers
(both layers of myometrium and endometrium) had a much
reduced thickness and were infiltrated by cells. Membranes
surrounding liquid filled cysts were also present. Sections from
Dox-treated infected mice showed an enlarged lumen and tissue
distortions but to a lesser extent than untreated infected animals.
In contrast, uterine horns from pG-treated infected mice did not
present any detectable anomaly and were comparable to control
uninfected uterine horns.
Discussion
To the best of our knowledge, this is the first demonstration that
pG-treatment of Chlamydia-infected cells in vitro reproducibly
induces bacterial death.
Classical persistence has been defined in vitro on the basis of two
main criteria: a non-developing inclusion containing few modestly
enlarged, viable RBs [27], and reversibility, i.e. the capacity of PFs
to resume a normal cycle after removal of the persistence inducer,
and to produce an infectious progeny [2,28,29].
Although the present study was based on an in vitro model of
pG-treatment of C. trachomatis-infected cells previously used by
other groups, we have observed reproducibly that pG treatment
allows a continuous growth of inclusions containing very few
enlarged, noninfectious Chlamydiaceae forms. Other groups have
reported similar findings [13,15,18–20,30].
These observations, coupled with the fact that pG-forms of C.
trachomatis cannot revert to infectious EBs after removal of pG even
after 48 hpi, indicate that pG-forms differ from ‘‘classical’’ PFs.
Recently, Ouellete et al. have used very low doses of pG (8 IU/
mL) to treat C. trachomatis serovar L2-infected HeLa cells [31]. In
this study, they showed the development of large abnormal
bacterial bodies similar to what we observe in our study. In both
studies, even minute amounts of pG (0.08 IU/mL) reduce the
infectious progeny by 4 logs. Ouellette et al. have tested different
beta-lactams and have shown that pG is the most effective to
reduce the infectious progeny from infected cell cultures. We
confirmed this finding. Interestingly, when they removed pG from
the culture medium at 24hpi, they recovered a small infectious
activity, which is in agreement with what we have described in the
present study. Indeed, we observed that when pG is removed from
L2-infected cultures earlier than 48hpi, there is a significant
probability that all initial EBs have not yet converted to RBs
before the withdrawal of pG, and RBs only are sensitive to pG.
Thus, some initial EBs could be converted to RBs after the
removal of pG and then be able to multiply and produce new
infectious EBs.
Finally, we have shown in our study that a brief (2 hrs) pG-
treatment is sufficient to trigger an inhibition of chlamydial
suppression of host cell apoptosis.
As it was hypothesized by Johnson and Hobson 35 years ago,
but not demonstrated, the addition of pG soon after infection can
inhibit bacterial virulence and allow the host cell to activate
defense mechanisms, such as the targeting of lysosomes to the
bacterial compartment [15].
We demonstrate here that pG treatment leads to the
recruitment of active cathepsin D into pG-forms as early as 3 h
post antibiotic treatment. Importantly, we observed the penetra-
tion of intact lysosomes into the atypical inclusion. The absence of
fusion of lysosomes with the membrane of the inclusion is an
unexpected finding, although the translocation of lipid droplets
into inclusions has recently been described, suggesting a potential
mechanism for the translocation of large intact bodies across the
inclusion membrane [32]. The formation of this degradative
environment leads to a complete lack of transcription of bacterial
RNA such as the vital and highly transcribed pre-16S-rRNA.
Another report showed that genes remain inactivated after
withdrawal of pG from cultures of C. pneumoniae, suggesting that
bacteria are dead following pG-treatment [22]. In contrast, the
prevention of fusion of lysosomes with bacteria, and the
maintenance of bacterial RNA transcription are central to
chlamydial development, so they must be kept during reversible
persistence induced by other stimuli [33–37].
We have tried to block the fusion of lysosomes with bacteria
using inhibitors of the classical pathways that we suspected to be
involved. Our results show that this phenomenon occurs via a
pathway insensitive to NH4Cl, known to inhibit the fusion of
lysosomes with cargo, and that the activation of cathepsin D in pG
forms is independent of the activation of a lysosomal H+v-ATPAse
(data not shown). Thus, mechanisms involved remain to be
elucidated.
The consequences of pG treatment of Chlamydiaceae in vitro
remain a matter of significant debate in the literature. Our findings
are in agreement with reports on the deleterious effect of ß-lactams
on C. trachomatis or C. pneumoniae infections in vitro [15,21,22].
However, other studies appear in contradiction, in infections by C.
psittacci [13,38] or C. trachomatis [20,30]. A detailed inspection of
the associated protocols revealed that most authors included CHX
muridarum. After 10 days, animals were treated or not with 10 mg/mL of doxycycline or penicillin G for an additional 20 days. Mice were sacrificed at
90 days post infection. B- Infection course in infected mice either left untreated (black diamond), or treated per os with Dox (white triangle) or with pG
(black square). Each data point represents the mean 6 standard deviation of the number of inclusion forming units recovered from vaginal swabs
collected from at least 5 mice per group. *: p, 0.05 compared to pG- and Dox-groups, **: p, 0.01 compared to pG- and Dox-groups, ***: p, 0.001
compared to pG- and Dox-groups. NS: non-significant compared to pG- and Dox-groups. ns: non-significant compared to Dox-group. C- Mice were
infected with C. muridarum and treated as described in Figure 6A. Ninety days after infection, mice were sacrificed to collect and examine their entire
genital tract. The pictures are representative of the cohorts studied. The presence of cysts is indicated by arrows, and hydrosalpinges by arrowheads.
D- After sacrifice of the mice, the genital tract was isolated and the percentage of mice presenting uterine lesion in at least one horn was determined.
Non-infected group (n = 10), infected non-treated group (n = 35), infected + Dox group (n = 29), infected + pG group (n = 36). * correspond to p, 0.05,
** correspond to p,0.01. E- After sacrifice, the severity of uterine lesion (cysts and hydrosalpinges) was scored as described in material and methods.
The number of uterine horns without (0) or with varying degrees (1 to 3) of lesion severity was reported. The Mann Whitney test was used to compare
the differences in lesion severity score between the different groups of mice, as indicated in the figure. NS: non-significant; ** correspond to p, 0.01;
*** correspond to p, 0.001.
doi:10.1371/journal.pone.0083511.g006
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in cultures to control cell growth during infection. We have shown
that CHX treatment of pG-treated infected cells allows the
recovery of an infectious progeny after removal of pG, possibly by
inhibiting the process of lysosomes fusion to the bacterial
compartment or the apoptosis of infected cells. This observation
strongly suggests that the use of CHX is a likely explanation for the
different results.
However, other causes might be: a too short incubation time with
pG, pG addition outside of its window of action (RB stage), or
inadequate pG dosage for the number of infected cells. Each of these
conditions would lead to an incomplete bactericidal effect, leaving
some bacteria alive, but not to persistence followed by reversion. We
have demonstrated that pG acts on RBs of C. trachomatis serovar L2
mostly between 12 hpi and 32 hpi, providing important information
on the window of action of pG on bacteria. Observations using
confocal microscopy show that EBs of C. trachomatis serovar L2
differentiate into RBs,10 hpi in HeLa cells and that pG causes the
formation of pG-forms after only 3-4h of co-incubation with infected
cells. If the molecular targets of antibiotics such as tetracycline
(targeting 30S ribosomal subunit) and macrolide (targeting the 50S
subunit) are well defined in Chlamydiaceae and other bacteria,
identifying the pG target in the context of the Chlamydia paradox is
a challenge, as penicillin usually binds to and inhibits penicillin-
binding proteins (PBP), involved in peptidoglycan synthesis in other
bacteria [12,39]. Three PBP have been identified in C. trachomatis but
the biosynthetic pathway of peptidoglycan is incomplete in this
bacterium and peptidoglycan has yet to be definitely detected
[12,39]. This suggests that the effect of penicillin on Chlamydiaceae
might not be related to peptidoglycan synthesis. However, Chlamydia
could produce a covalently closed, glycan-less polypeptide present in
the bacterial wall and whose synthesis is b-lactam sensitive. Its
absence could affect the development and the viability of the bacteria
by either modifying the structure of the bacterial wall or affecting RB
division [12,40,41]. Thus, in the presence of b-lactams, the rigidity of
the outer membrane of RBs and the regulation of porins may be
compromised [42,43]. This may render the bacteria more sensitive
to osmotic and redox stresses and thus explain the abnormal swelling
of RBs, and their continued growth along with the inclusion, both
phenotypes induced in the presence of pG.
C. trachomatis also synthesizes and translocates proteins into the
host cell via type III -dependent or -independent secretion systems
[44–47]. Such factors manipulate host cell pathways including the
prevention of fusion of lysosomes with the bacteria. Any structural
modification of the bacterial wall could inhibit the secretion of
virulence factors and indirectly affect bacterial viability.
Our data show that pG-treatment of Chlamydia-infected cells in
culture kills the bacteria. We tested this bactericidal effect in vivo by
infecting mice intra-vaginally by C. muridarum and then treating
them with doxycycline or pG. In our study, 60% of C57BL/6
females infected by C. muridarum developed upper genital tract
lesions that can be hydrosalpinx and/or inflammatory cysts along
the uterine horns. These observations are consistent with what has
been published in recent studies [48–49]. We have shown that
both antibiotic treatments lead to a faster elimination of Chlamydia
from the lower genital tract, but only pG treatment significantly
protected mice from the development of uterine inflammatory
lesions, monitored both macroscopically and microscopically in
paraffin sections. In accordance with our study, previous work
showed that C57BL/10 mice vaginally-infected with C. muridarum
and treated by Dox between 10 and 24 days post infection (10–30
days post-infection in our study) eliminated vaginal infection
within 5 days [50]. Despite this rapid clearance, more than 25% of
those mice showed hydrosalpinx at 55 days post infection, which is
in agreement with our results (49623% of mice presenting tubal
lesions 90 days post infection). The difference in percentages of
mice with lesions between the two studies could result from the fact
that we have included animals presenting uterine cysts, and also
that we sacrificed mice 35 days later than in the other study,
leaving time for lesions to develop.
Such an effect of molecules from the ß-lactam family had
already been reported in other in vivo studies, but it could not be
explained since b-lactams were claimed to induce the persistence
of Chlamydiaceae in vitro. These previous studies had shown that b-
lactams have a protective activity in models of respiratory and
genital infections in mice [51,52]. Such unexplained protective
effect justified the use of b-lactams resistant to penicillinases or a
combination of penicillin and b-lactamase inhibitors, which are
still considered excellent alternatives to standard treatment against
human chlamydiosis. They have been used particularly during
pregnancy [53,54], in PID including acute salpingitis and cervicitis
[55–63], and in male urethritis [64].
In conclusion, our data provide the basis of a cellular
mechanism for the protective effect of ß-lactam antibiotics against
chlamydial infection that had been previously observed in vivo.
These results support the physiological relevance of our findings
and their potential therapeutic applications.
Supporting Information
Figure S1 The effect of pG on Chlamydiaceae is
independent of host cell type, serovar, biovar or species
of the bacteria, but is dependent on eukaryotic protein
neosynthesis. A-THP-1, a human monocyte/macrophage
tumor cell line, RL95-2, a human endometrial tumor cell line
and HeLa, a human cervical tumor cell line were infected by
either C. trachomatis serovar L2 (C.t L2), or serovar D (C.t D), or
Chlamydia muridarum. Infected cells were either treated with pG
(100 IU/ml) at 3 hpi or left untreated. Cells were fixed at 24 hpi
(RL95-2/C.t L2; HeLa/C.t D; HeLa/C. muridarum) or at 48 hpi
(THP-1/C.t L2; THP-1/C.t D) and stained using Hoechst (blue)
and anti-Chlamydia sp. antibody (green). Scale bar: 10 mm. The
experiment has been repeated four times. B-HeLa cells infected by
C. trachomatis serovar L2 were treated at 3 hpi either with different
concentrations of pG (from 0.01 to 100 IU/mL) or left untreated.
In some samples (+), pG was removed at 48 hpi from culture
medium and cultures were continued for 52 h. At 100 hpi, cellular
extracts were processed for the titration of recovered infectious
activity. The experiment has been repeated three times. C- HeLa
cells were treated with cycloheximide (CHX) at 1 mg/ml, 4 h
before infection. Cells were then infected by C. trachomatis serovar L2
(IFU=1) and treated with pG (100 IU/ml) at 3 hpi or left
untreated. In some experimental conditions, pG was washed away
(pG removal) from culture medium at 24 hpi and the culture was
continued for 76h. At 100 hpi, cells layers (left panel) and
supernatants (right panel) were collected and processed for the
titration of recovered infectious activity. The experiment has been
repeated three times. *: statistically significant difference (p,0.05),
***: statistically significant difference (p,0.001).
(TIF)
Figure S2 Cathepsin D is retained in pG-forms of
Chlamydia trachomatis independently of biovar and
host cells. RL95-2 and HeLa cells were infected with C.
trachomatis serovar L2 or C. trachomatis serovar D, respectively, and
treated with pG at 3 hpi or left untreated. At 24 hpi, cells were
fixed and stained with Hoechst, anti-Chlamydia sp. antibody and
anti-Cathepsin D. The experiment has been repeated three times.
(TIF)
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Figure S3 Uterine horn pathology is significantly de-
creased in C57Bl/6 mice infected with C.muridarum
and treated with pG. Mice were infected or not with
C.muridarum, treated or not with antibiotics (Dox or pG) and
sacrificed at ninety days after infection (cf. legends to Figure 6).
Histopathological evaluation was performed as described in
Materials and Methods. All pictures are presented at the same
magnification scale (X40). Liquid filled cysts are marked with
arrows in untreated infected mice. 1: lumen, 2: uterine epithelium;
3: chorion, 2-3: endometrium; 4-5: myometrium, 4: circular
muscle layer, 5: longitudinal muscle layer; 6 serosa; 7: vascular
layer between the two muscle layers.
(TIF)
Movie S1 Time-lapse video showing the recruitment of
lysotracker-positive compartments into bacterial inclu-
sions of pG-treated infected cells. Inclusion (I), Nucleus (N).
The experiment has been reproduced four times. Magnification: X
400. Scale bar: 10 mm. (For still images see figure 4D).
(MOV)
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